度普利尤单抗作为慢性咽鼓管功能障碍合并鼻息肉型慢性鼻窦炎的治疗选择：基于病例的观察。
Dupilumab as a Therapeutic Option in Chronic Eustachian Tube Dysfunction and Chronic Rhinosinusitis with Nasal Polyposis: A Case-Based Observation.
文献信息
| PMID | 42867349 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Holger Sudhoff |
| 作者单位 | Department of Otorhinolaryngology, Head and Neck Surgery, Bielefeld University Kopfzentrum Bielefeld, Bielefeld, Germany. |
| 期刊 | The journal of international advanced otology |
| SCI 分区 | Q3 |
| IF | 1.3 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 鼻科 |
中文摘要
背景： 报告首例记录在案的、在接受度普利尤单抗治疗的重度鼻息肉型慢性鼻窦炎（CRSwNP）患者中，难治性扩张性咽鼓管功能障碍（ETD）完全缓解的病例。
方法： 四例连续就诊的、患有长期难治性扩张性ETD、重度CRSwNP和哮喘、且对多次鼻窦和乳突手术无反应的患者，接受了度普利尤单抗治疗。
结果： 度普利尤单抗在6周内使CRSwNP和扩张性ETD症状均完全缓解。听力计检查和咽鼓管测压法证实中耳功能恢复。
结论： 度普利尤单抗可能为与2型炎症相关的扩张性ETD患者提供一种新的治疗选择。需要进一步的前瞻性研究来评估其长期疗效。
英文摘要
BACKGROUND: To report the first documented case of complete resolution of refractory dilatory Eustachian tube dysfunction (ETD) following dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP).
METHODS: Four consecutive patients with longstanding refractory dilatory ETD, severe CRSwNP, and asthma, unresponsive to multiple sinus and mastoid surgeries, were treated with dupilumab.
RESULTS: Dupilumab resulted in complete remission of both CRSwNP and dilatory ETD symptoms within 6 weeks. Audiometry and tubomanometry confirmed restoration of middle ear function.
CONCLUSION: Dupilumab may offer a novel therapeutic option for patients with dilatory ETD associated with type 2 inflammation. Further prospective studies are needed to assess its long-term efficacy.